Recombinant Interleukin‐18 Protects against DisseminatedCandida albicansInfection in Mice | Zendy

Rogier J. L. Stuyt | Zendy; Mihai G. Netea | Zendy; J. Han van Krieken | Zendy; Jos W.M. van der Meer | Zendy; Bart Jan Kullberg | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Recombinant Interleukin‐18 Protects against DisseminatedCandida albicansInfection in Mice

Author(s) -

Rogier J. L. Stuyt,

Mihai G. Netea,

J. Han van Krieken,

Jos W.M. van der Meer,

Bart Jan Kullberg

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/382955

Subject(s) - candida albicans , splenocyte , immunotherapy , corpus albicans , adjuvant , recombinant dna , immunology , interleukin 2 , cytokine , biology , microbiology and biotechnology , endogeny , systemic candidiasis , inflammation , interleukin , interferon gamma , medicine , spleen , immune system , endocrinology , biochemistry , gene

Endogenous interleukin (IL)-18 is necessary for host defense against candidiasis. Prophylactic treatment of Candida albicans-infected mice with recombinant murine (r) IL-18 decreased mortality, which was accompanied by a decreased outgrowth of yeasts in the kidneys 1 day after infection. Therapeutic administration of rIL-18 also resulted in decreased outgrowth of C. albicans in the kidneys and increased levels of interferon- gamma, both in the circulation and after in vitro stimulation of splenocytes with C. albicans. Histopathologic analysis of the kidneys showed increased inflammation and decreased growth of C. albicans in rIL-18-treated mice. In conclusion, rIL-18 improves outcome of disseminated candidiasis in mice and may prove useful as adjuvant immunotherapy of fungal infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research